These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35403431)

  • 21. Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variants.
    Chakraborty S; Saha A; Saha C; Ghosh S; Mondal T
    Biochem Biophys Res Commun; 2022 Oct; 627():168-175. PubMed ID: 36041326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
    Starr TN; Greaney AJ; Addetia A; Hannon WW; Choudhary MC; Dingens AS; Li JZ; Bloom JD
    Science; 2021 Feb; 371(6531):850-854. PubMed ID: 33495308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
    Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
    J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain.
    Patrick C; Upadhyay V; Lucas A; Mallela KMG
    J Mol Biol; 2022 Jul; 434(13):167622. PubMed ID: 35533762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations.
    Verkhivker G; Agajanian S; Kassab R; Krishnan K
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Omicron Variant Binds to Human Cells More Strongly than the Wild Type: Evidence from Molecular Dynamics Simulation.
    Nguyen HL; Thai NQ; Nguyen PH; Li MS
    J Phys Chem B; 2022 Jun; 126(25):4669-4678. PubMed ID: 35723978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
    Focosi D; Maggi F
    Rev Med Virol; 2021 Nov; 31(6):e2231. PubMed ID: 33724631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
    Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
    Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
    Baum A; Ajithdoss D; Copin R; Zhou A; Lanza K; Negron N; Ni M; Wei Y; Mohammadi K; Musser B; Atwal GS; Oyejide A; Goez-Gazi Y; Dutton J; Clemmons E; Staples HM; Bartley C; Klaffke B; Alfson K; Gazi M; Gonzalez O; Dick E; Carrion R; Pessaint L; Porto M; Cook A; Brown R; Ali V; Greenhouse J; Taylor T; Andersen H; Lewis MG; Stahl N; Murphy AJ; Yancopoulos GD; Kyratsous CA
    Science; 2020 Nov; 370(6520):1110-1115. PubMed ID: 33037066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
    Huang KA; Zhou D; Tan TK; Chen C; Duyvesteyn HME; Zhao Y; Ginn HM; Qin L; Rijal P; Schimanski L; Donat R; Harding A; Gilbert-Jaramillo J; James W; Tree JA; Buttigieg K; Carroll M; Charlton S; Lien CE; Lin MY; Chen CP; Cheng SH; Chen X; Lin TY; Fry EE; Ren J; Ma C; Townsend AR; Stuart DI
    Theranostics; 2022; 12(1):1-17. PubMed ID: 34987630
    [No Abstract]   [Full Text] [Related]  

  • 36. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
    VanBlargan L; Errico J; Halfmann P; Zost S; Crowe J; Purcell L; Kawaoka Y; Corti D; Fremont D; Diamond M
    Res Sq; 2021 Dec; ():. PubMed ID: 34981042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
    Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
    Front Immunol; 2022; 13():871874. PubMed ID: 35898497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach.
    Ranjan P; Neha ; Devi C; Devar KA; Das P
    Microb Pathog; 2022 Aug; 169():105619. PubMed ID: 35690234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
    Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
    EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.